SOURCE: Micro Imaging Technology, Inc.

Micro Imaging Technology, Inc.

November 18, 2011 08:00 ET

StockTradersTalk Interviews Micro Imaging Technology, Inc. Chairman and CEO, Michael Brennan

SAN CLEMENTE, CA--(Marketwire - Nov 18, 2011) - Michael Brennan, CEO and Chairman of Micro Imaging Technology, Inc. (OTCBB: MMTC) (OTCQB: MMTC), the developer of a patented stand-alone optically-based pathogenic bacteria identification system, was interviewed November 17, 2011. The interview provided an overview of the Company, its technology and an update on the Company's recent achievements. In addition, it provides a brief outlook of how MIT views its business opportunities in the coming months.

The interview was held on November 17, and can be heard at The interactive question and answer session can be accessed from the main room at An archived recorded version can be found on the homepage of Stock Traders Talk at, following the live interview.

About StockTradersTalk:

StockTradersTalk is a web resource portal for stock investors. We provide an open source chat room that allows traders to converse freely in an open forum. Members can create and maintain their own tickers and companies to provide up to date information for potential shareholders. Message boards are provided for each ticker that has real time updates and allow live conversations about the company. This is a unique feature that only we provide. Our goal is to provide an open forum for investors to freely express opinions, ideas, and investment opportunities with other members of As always, it's your site... enjoy.

About Micro Imaging Technology:

MIT is a California-based public company that has developed and patented a Microbial Identification System that revolutionizes the pathogenic bacteria diagnostic process -- specifically focusing on food safety. The MIT 1000A identifies bacteria in less than five (5) minutes and with a material cost of pennies -- adding credence to MIT's claims of being able to annually save thousands of lives and tens of millions of dollars in health care costs.

Revenues for all rapid testing methods exceed $5 billion annually -- with food safety accounting for over $3.5 billion, which is expected to surpass $4.7 billion by 2015 according to BCC Research. In addition, the recently passed "New" U.S. Food Safety Bill is expected to further accelerate the current annual growth rate of 6.6 percent.

MIT previously completed an extensive evaluation by the AOAC Research Institute (AOAC RI) which included rigorous independent testing and thorough reviews by its expert examiners, including the U.S. Department of Agriculture. This evaluation process resulted in MIT being awarded the prestigious AOAC RI Certificate of Performance Testing (Certificate No. 060901). The AOAC RI Report is available from the Company.

MIT also demonstrated the ability to detect and identify, within several minutes, the microbes Escherichia coli, Listeria, Salmonella, Staphylococcus aureus, and other pathogenic bacteria. This identification process was also verified by North American Science Associates, Inc. ("NAMSA"), an independent and internationally recognized bioscience testing laboratory. The NAMSA Test Report is also available from the Company and, in MIT's opinion, demonstrates the accuracy, speed and cost effectiveness of the System over conventional processes. The NAMSA Report is also available from the Company.

This release contains statements that are forward-looking in nature. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions are forward-looking statements. These statements are made based upon information available to the Company as of the date of this release, and we assume no obligation to update any such forward-looking statements. These statements are not guarantees of future performance and actual results could differ materially from our current expectations. Factors that could cause or contribute to such differences include, but are not limited to dependence on suppliers; short product life cycles and reductions in unit selling prices; delays in development or shipment of new products; lack of market acceptance of our new products or services; inability to continue to develop competitive new products and services on a timely basis; introduction of new products or services by major competitors; our ability to attract and retain qualified employees; inability to expand our operations to support increased growth; and declining economic conditions, including a recession. These and other factors and risks associated with our business are discussed from time to time within our filings with the U.S. Securities and Exchange Commission, reference MMTC:

Contact Information